Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure.
Myocardial right ventricular (RV) hypertrophy due to pulmonary hypertension is aimed at normalizing ventricular wall stress. Depending on the degree of pressure overload, RV hypertrophy may progress to a state of impaired contractile function and heart failure, but this cannot be discerned during the early stages of ventricular remodeling. We tested whether critical differences in gene expression profiles exist between ventricles before the ultimate development of either a compensated or decompensated hypertrophic phenotype. Both phenotypes were selectively induced in Wistar rats by a single subcutaneous injection of either a low or a high dose of the pyrrolizidine alkaloid monocrotaline (MCT). Spotted oligonucleotide microarrays were used to investigate pressure-dependent cardiac gene expression profiles at 2 wk after the MCT injections, between control rats and rats that would ultimately develop either compensated or decompensated hypertrophy. Clustering of significantly regulated genes revealed specific expression profiles for each group, although the degree of hypertrophy was still similar in both. The ventricles destined to progress to failure showed activation of pro-apoptotic pathways, particularly related to mitochondria, whereas the group developing compensated hypertrophy showed blocked pro-death effector signaling via p38-MAPK, through upregulation of MAPK phosphatase-1. In summary, we show that, already at an early time point, pivotal differences in gene expression exist between ventricles that will ultimately develop either a compensated or a decompensated phenotype, depending on the degree of pressure overload. These data reveal genes that may provide markers for the early prediction of clinical outcome as well as potential targets for early intervention.
Buermans
Henk P J
HP
Laboratory for Physiology, VU University Medical Center, Amsterdam, The Netherlands.
Redout
Everaldo M
EM
Schiel
Anja E
AE
Musters
René J P
RJ
Zuidwijk
Marian
M
Eijk
Paul P
PP
van Hardeveld
Cornelis
C
Kasanmoentalib
Soemini
S
Visser
Frans C
FC
Ylstra
Bauke
B
Simonides
Warner S
WS
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000235:genetics; D000252:Calcium-Transporting ATPases / Q000235:genetics; D017931:DNA Primers; D004195:Disease Models, Animal; D020869:Gene Expression Profiling; D006333:Heart Failure / Q000235:genetics*; D006973:Hypertension / Q000235:genetics; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000235:genetics; D017379:Hypertrophy, Left Ventricular / Q000235:genetics*; D017380:Hypertrophy, Right Ventricular / Q000235:genetics*; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis; D016133:Polymerase Chain Reaction; D012313:RNA / Q000235:genetics / Q000302:isolation & purification; D012333:RNA, Messenger / Q000235:genetics*; D051381:Rats; D017208:Rats, Wistar; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases
D017931:DNA Primers; D012333:RNA, Messenger; D012313:RNA; D009320:Atrial Natriuretic Factor; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D000252:Calcium-Transporting ATPases